This was the stock's fifth consecutive day of losses.

Shares of Kenvue led S&P 500 decliners Tuesday after the consumer health giant's chief executive indicated the firm faces ...

On January 16, Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend of $0.205 per share, having raised it by 2.5% in July 2024. The company has been growing its payments for 62 consecutive years.

Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on ...

Kenvue Inc. (NYSE:KVUE) operates as a consumer health company. Anna Lizzul from Bank of America Securities reiterated a “Buy” rating on the company’s stock with the price target of $25.00.

Kenvue faces demand weakness, retailer destocking, and price cuts, raising concerns about structural issues and recovery.

Kenvue Inc. (NYSE:KVUE) reported adjusted earnings per share (EPS) of $0.26 in fiscal Q4 2024, which is in line with analyst expectations. Although the company faced some headwinds, ...

Kenvue Inc. (NYSE:KVUE) is among the Best Beauty Stocks and the world’s largest pure-play consumer health company by revenue, with $15 billion in annual revenue.

Kenvue Debuts on Fortune 500 List. SUMMIT, N.J., June 02, 2025--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has ...

New Jersey-based Kenvue Inc. is a consumer health company operating across the Americas, Europe, EMEA, and the Indo-Pacific.